FDA Issues New Guidance on Assessing REMS

Drug Industry Daily
A A
The FDA released two draft guidances on Thursday outlining the agency’s latest thinking on assessments of risk evaluation and mitigation strategy (REMS) programs.

To View This Article:

Login

Subscribe To Drug Industry Daily